Talk:Wearable cardioverter defibrillator

Untitled
I saw the lack of citations thing at the top, and I just came from the Zoll page for the device. The writing for the first portion of the article is pretty much just copy-pasted from the FAQ for the Zoll LifeVest  http://lifevest.zoll.com/patients/patient-faqs.asp

This article needs to reflect that not all cardiologists agree that the Zoll LifeVest is necessary or beneficial. https://www.healthnewsreview.org/2018/02/wearable-defibrillators-may-save-lives-but-patients-and-doctors-question-at-what-cost/ --Msr69er (talk) 12:22, 12 April 2018 (UTC)

Should There be a Separate Article?
I know it's a little off-topic but do you think that there should be a separate article for ZOLL Medical Corporation?

Side Note: Please excuse me for any errors, I am new to Wikipedia Editing. Elzeba (talk) 23:21, 31 August 2020 (UTC)

Claim without Reference
Hello. "The WCD does not require bystander intervention and has a 98 percent first treatment shock success rate for resuscitating patients from SCA." This piece of information in the description section is a huge claim and shouldn't be included in the draft without a strong reference. Please look into this. --AIstruckbob (talk) 12:25, 29 March 2022 (UTC)

A Commons file used on this page or its Wikidata item has been nominated for deletion
The following Wikimedia Commons file used on this page or its Wikidata item has been nominated for deletion: Participate in the deletion discussion at the. —Community Tech bot (talk) 17:07, 9 December 2022 (UTC)
 * Table 1. Wearable CD Evidence Base Summary.png

Medical Considerations section?
Perhaps a section on medical or lifestyle considerations should be added. It would be useful for information including, for example, how the device interacted with various medical tests such as EEGs, EMGs, SSEPs, MEPs, CT Scans, and other such tests. AevumNova (talk) 07:04, 29 June 2023 (UTC)

Request Edit
I work for Kestra Medical Technologies, and we are proposing changes to this page because it contains outdated information as of July 2021 when the FDA approved a second wearable cardioverter defibrillator, the ASSURE WCD system by Kestra Medical Technologies, Inc. The following proposed edits are meant to make the terminology more generic and remove branded terms and product category descriptions.

Under the Description section


 * The second paragraph is mostly copy-pasted from the FAQ for the Zoll LifeVest: http://lifevest.zoll.com/patients/patient-faqs.asp. The second sentence in the second paragraph uses language that is only applicable to the ZOLL WCD: “It consists of a vest, an electrode belt and a monitor. The vest with the electrode belt is worn under the clothing during the entire day. The WCD should only be removed when taking a shower or bath. The monitor can either be worn around the waist or over a shoulder strap. The electrodes and wires, placed on the inner sides of the vest and electrode belt, lie directly on the skin. The monitor constantly records heart rate and rhythm.” Please update to: “It consists of a fabric garment, electrodes located in the fabric garment for sensing and delivering an electrical shock, and a battery-powered device that monitors the patient and connects to the electrodes and defibrillation pads. The WCD is worn under the clothing during the entire day. The WCD should only be removed when taking a shower or bath. The electrodes lie directly on the skin. The monitoring device constantly records heart rate and rhythm.”


 * Under the first image (Floating-LifeVest-HighRes 4000.jpg), update the description to "ZOLL LifeVest WCD showing vest and power supply” because it is showing the ZOLL system.


 * Under the second image (LifeVest Body HighRes 4000.jpg), update description to “ZOLL LifeVest WCD in situ” because it is showing the ZOLL system.

Under History


 * There is an unnecessary hyphen in the eighth sentence of the first paragraph that begins: “An external, wearable cardioverter-defibrillator….” Please remove the hyphen to read “An external, wearable cardioverter defibrillator...” as the product does not require hyphenation.


 * Please remove the first sentence in the fifth paragraph: “ZOLL Medical Corporation, meanwhile an Asahi Kasei Group Company, acquired the LIFECORE business in 2006.” as it is redundant given the previous paragraph.


 * At the bottom of the section, please insert the following sentence to reflect the additional wearable defibrillator now on the market: “In July 2021, the FDA approved a second WCD product for the market: the ASSURE WCD system by Kestra Medical Technologies, Inc. This new device has an alternative fabric and garment style specifically for women.”


 * Add these images to this section with the following descriptions at the end of the section to show ASSURE WCD system: Link to image: https://commons.wikimedia.org/wiki/File:ASSURE_WCD_system_-_Garment,_Style_B.jpg, Caption: The ASSURE WCD system with SensorFit Garment, Style B


 * Link to image: https://commons.wikimedia.org/wiki/File:ASSURE_WCD_system_-_Garment,_Style_A.jpg, Caption: The ASSURE WCD system with SensorFit Garment, Style A

Under Working mechanism of the WCD


 * Update the first sentence of the first paragraph from ”The WCD consists of a comfortable, lightweight washable vest, an electrode belt and a monitor. The battery-powered monitor can be worn over a shoulder strap or in a holster around the waist (Fig. 1 and 2). The monitor collects the data from the electrocardiography (ECG) electrodes and performs the appropriate calculations according to the pre-planned settings, which are programmed by the treating physician. It also contains the capacitors for the defibrillation energy.” to ”The WCD consists of a comfortable, lightweight washable fabric garment, electrodes located in the fabric garment for sensing and delivering an electrical shock, and a battery-powered device that monitors the patient and connects to the electrodes and defibrillation pads. The battery-powered monitoring device can be worn over the shoulder  or around the waist (Fig. 1 and 2). The monitoring device collects the data from the electrocardiography (ECG) electrodes and performs the appropriate calculations according to the pre-planned settings, which are programmed by the treating physician. It also contains the capacitors for the defibrillation energy.” The current version is specifically written for the ZOLL product. The second version makes the information more generic for the entire product class.


 * Remove the fifth sentence of the first paragraph: “The default setting is: 1) VT detection 150-199 beats/minute; 2) VF detection ≥200 beats/minute.” This is inaccurate because default settings change based on the manufacturer.


 * The second and third paragraphs are currently written specifically about the ZOLL device. Please update the first paragraph to make the language more generic and applicable to the entire product class: “THE WCD uses dry, non-adhesive ECG electrodes to continuously monitor the patient's heart rhythm. Three defibrillation electrodes are placed in the fabric garment, one on the chest (approximately at the level of the apex of the heart) and two on the back (between the shoulder blades). The ECG electrodes are placed inside the fabric garment on the chest providing two independent ECG leads. Prior to delivering a therapeutic shock, the dry defibrillator electrodes automatically deploy conductive gel to protect the skin from possible injury from the treatment. The WCD can deliver up to five consecutive shocks per sequence. Life-saving therapy typically occurs within a minute of the onset of an arrhythmia. The patient is warned when a treatment sequence has been started, e.g. by siren alarms and spoken information. Through interaction with the WCD, an unjustified shock delivery can be prevented by the patient as long as she/he is conscious. If the patient fails to respond, e.g., because the patient has lost consciousness due to an arrhythmia, gel is automatically ejected from under the defibrillation electrodes. If the arrhythmia resolves on its own, no treatment shock is delivered. Action from bystanders is not required, but they are warned by voice information not to touch the patient during defibrillation and to call emergency services.”


 * Please update the second paragraph of this section to make the languagee more generic and applicable to the entire product class: “The patient receives two rechargeable batteries for the WCD. One will be used to operate the monitoring device, the other is charged for daily replacement. Conspicuous ECG sequences or treatments are automatically transmitted to a secure server. The treating physician can view and analyze them via password-protected access. Before a WCD is handed to a patient, the WCD is fitted to the patient for accurate ECG signal detection and the patient receives detailed training to ensure correct handling of the WCD.”

Under Temporary living with the WCD


 * Please update the second paragraph from ”Currently a study on the use of the WCD started in UK.” to correct the grammar by replacing it with “Currently a study on the use of the WCD has been started in the UK.”


 * Please update the second sentence in the third paragraph from, “The manufacturer also advises to avoid activities in loud and/or high vibration environments due to the possibility of missing an alert from WCD.” to “It is also advised to avoid activities in loud and/or high vibration environments due to the possibility of missing an alert from the WCD.” This corrects the grammar and makes the terminology more generic.

Under Assessment of usefulness


 * Please insert the word “of” before ”patients” in the second sentence of the first paragraph: ”Some cardiologists agree that a wearable cardioverter defibrillator is medically only necessary, compared to standard medical treatment for a subset of patients at risk for SCA, however medical guidelines give a clear understanding of the right diagnosis with benefits for the WCD.”


 * The second paragraph discusses an FDA Safety Alert that only applies to the Zoll product. Change the last sentence of the paragraph from “Copies of the alert were included in all subsequent shipments of the device.” to “Copies of the alert were included in all subsequent shipments of the ZOLL device.”

Under Indications for receiving a WCD


 * Correct the first sentence from “The WCD is generally recommended as temporary therapy for all patients who are at risk of SCD and can be prescribed in UK as a monthly rental device.” to “The WCD is generally recommended as temporary therapy for all patients who are at risk of SCD and can be prescribed in the UK as a monthly rental device.”

Patrick98115 (talk) 17:34, 6 November 2023 (UTC)
 * Given the complexity of the requested changes, I'm going to ask that the COI editor make use of the template in all instances where currently existing text is to be changed with revised text. Regards,  Spintendo  22:17, 6 November 2023 (UTC)


 * I work for Kestra Medical Technologies, and we are proposing changes to this page because it contains outdated information as of July 2021 when the FDA approved a second wearable cardioverter defibrillator, the ASSURE WCD system by Kestra Medical Technologies, Inc. The following proposed edits are meant to make the terminology more generic and remove branded terms and product category descriptions.
 * Under the Description section
 * The second paragraph is mostly copy-pasted from the FAQ for the Zoll LifeVest: http://lifevest.zoll.com/patients/patient-faqs.asp. The second sentence in the second paragraph uses language that is only applicable to the ZOLL WCD. Please update the old text to this new text:
 * Under the first image (Floating-LifeVest-HighRes 4000.jpg), update the description to "ZOLL LifeVest WCD showing vest and power supply” because it is showing the ZOLL system.
 * Under the second image (LifeVest Body HighRes 4000.jpg), update description to “ZOLL LifeVest WCD in situ” because it is showing the ZOLL system.
 * Under History
 * There is an unnecessary hyphen in the eighth sentence of the first paragraph that begins: “An external, wearable cardioverter-defibrillator….” Please remove the hyphen to read “An external, wearable cardioverter defibrillator...” as the product does not require hyphenation.
 * Please remove the first sentence in the fifth paragraph: “ZOLL Medical Corporation, meanwhile an Asahi Kasei Group Company, acquired the LIFECORE business in 2006.” as it is redundant given the previous paragraph.
 * At the bottom of the section, please insert the following sentence to reflect the additional wearable defibrillator now on the market: “In July 2021, the FDA approved a second WCD product for the market: the ASSURE WCD system by Kestra Medical Technologies, Inc. This new device has an alternative fabric and garment style specifically for women.”
 * Add these images to this section with the following descriptions at the end of the section to show ASSURE WCD system: Link to image: https://commons.wikimedia.org/wiki/File:ASSURE_WCD_system_-_Garment,_Style_B.jpg, Caption: The ASSURE WCD system with SensorFit Garment, Style B
 * Link to image: https://commons.wikimedia.org/wiki/File:ASSURE_WCD_system_-_Garment,_Style_A.jpg, Caption: The ASSURE WCD system with SensorFit Garment, Style A
 * Under Working mechanism of the WCD
 * Update the first sentence of the first paragraph. The current version is specifically written for the ZOLL product. The second version makes the information more generic for the entire product class.
 * Remove the fifth sentence of the first paragraph: “The default setting is: 1) VT detection 150-199 beats/minute; 2) VF detection ≥200 beats/minute.” This is inaccurate because default settings change based on the manufacturer.
 * The second and third paragraphs are currently written specifically about the ZOLL device. Please update the first paragraph to make the language more generic and applicable to the entire product class.
 * Please update the second paragraph of this section to make the language more generic and applicable to the entire product class.
 * Under Temporary living with the WCD
 * Please update the second paragraph. ”Currently a study on the use of the WCD started in UK.” to correct the grammar by replacing it with “Currently a study on the use of the WCD has been started in the UK.”
 * Please update the second sentence in the third paragraph. This corrects the grammar and makes the terminology more generic.
 * Under Assessment of usefulness
 * Please insert the word “of” before ”patients” in the second sentence of the first paragraph: ”Some cardiologists agree that a wearable cardioverter defibrillator is medically only necessary, compared to standard medical treatment for a subset of patients at risk for SCA, however medical guidelines give a clear understanding of the right diagnosis with benefits for the WCD.”
 * The second paragraph discusses an FDA Safety Alert that only applies to the Zoll product. Change the last sentence of the paragraph from “Copies of the alert were included in all subsequent shipments of the device.” to “Copies of the alert were included in all subsequent shipments of the ZOLL device.”
 * Under Indications for receiving a WCD
 * Correct the first sentence from “The WCD is generally recommended as temporary therapy for all patients who are at risk of SCD and can be prescribed in UK as a monthly rental device.” to “The WCD is generally recommended as temporary therapy for all patients who are at risk of SCD and can be prescribed in the UK as a monthly rental device.”
 * Patrick98115 (talk) 23:14, 26 February 2024 (UTC)
 * I have partially implemented the requested edits. The change "The manufacturer also advises" to "It is also advised" is not done, as the article itself cannot provide instructions for a reader, those directions must be attributed to the/a device manufacturer. Recon  rabbit  13:57, 26 June 2024 (UTC)
 * Thank you for taking the time to review and implement.
 * There are still a handful of statements that are specific to the Zoll device and don't apply to the entire WCD market.
 * From ‘Working Mechanism of the WCD’
 * "In the electrode belt, four dry, non-adhesive ECG electrodes continuously monitor the patient's heart rhythm. Three defibrillation electrodes are placed in the vest, one on the chest (approximately at the level of the apex of the heart) and two on the back (between the shoulder blades)."
 * The term 'vest' and 'electrode belt' are branded Zoll terms that are non-generic.
 * Please update to genericize the language: “THE WCD uses dry, non-adhesive ECG electrodes to continuously monitor the patient's heart rhythm. Three defibrillation electrodes are placed in the fabric garment, one on the chest (approximately at the level of the apex of the heart) and two on the back (between the shoulder blades). The ECG electrodes are placed inside the fabric garment on the chest providing two independent ECG leads. Prior to delivering a therapeutic shock, the dry defibrillator electrodes automatically deploy conductive gel to protect the skin from possible injury from the treatment. The WCD can deliver up to five consecutive shocks per sequence. Life-saving therapy typically occurs within a minute of the onset of an arrhythmia. The patient is warned when a treatment sequence has been started, e.g. by siren alarms and spoken information. Through interaction with the WCD, an unjustified shock delivery can be prevented by the patient as long as she/he is conscious. If the patient fails to respond, e.g., because the patient has lost consciousness due to an arrhythmia, gel is automatically ejected from under the defibrillation electrodes. If the arrhythmia resolves on its own, no treatment shock is delivered. Action from bystanders is not required, but they are warned by voice information not to touch the patient during defibrillation and to call emergency services.
 * The patient receives two rechargeable batteries for the WCD. One will be used to operate the monitoring device, the other is charged for daily replacement. Conspicuous ECG sequences or treatments are automatically transmitted to a secure server. The treating physician can view and analyze them via password-protected access. Before a WCD is handed to a patient, the WCD is fitted to the patient for accurate ECG signal detection and the patient receives detailed training to ensure correct handling of the WCD.”
 * Source: https://avive.life/blog/wearable-defibrillator/ Patrick98115 (talk) 18:54, 26 June 2024 (UTC)
 * "In the electrode belt, four dry, non-adhesive ECG electrodes continuously monitor the patient's heart rhythm. Three defibrillation electrodes are placed in the vest, one on the chest (approximately at the level of the apex of the heart) and two on the back (between the shoulder blades)."
 * The term 'vest' and 'electrode belt' are branded Zoll terms that are non-generic.
 * Please update to genericize the language: “THE WCD uses dry, non-adhesive ECG electrodes to continuously monitor the patient's heart rhythm. Three defibrillation electrodes are placed in the fabric garment, one on the chest (approximately at the level of the apex of the heart) and two on the back (between the shoulder blades). The ECG electrodes are placed inside the fabric garment on the chest providing two independent ECG leads. Prior to delivering a therapeutic shock, the dry defibrillator electrodes automatically deploy conductive gel to protect the skin from possible injury from the treatment. The WCD can deliver up to five consecutive shocks per sequence. Life-saving therapy typically occurs within a minute of the onset of an arrhythmia. The patient is warned when a treatment sequence has been started, e.g. by siren alarms and spoken information. Through interaction with the WCD, an unjustified shock delivery can be prevented by the patient as long as she/he is conscious. If the patient fails to respond, e.g., because the patient has lost consciousness due to an arrhythmia, gel is automatically ejected from under the defibrillation electrodes. If the arrhythmia resolves on its own, no treatment shock is delivered. Action from bystanders is not required, but they are warned by voice information not to touch the patient during defibrillation and to call emergency services.
 * The patient receives two rechargeable batteries for the WCD. One will be used to operate the monitoring device, the other is charged for daily replacement. Conspicuous ECG sequences or treatments are automatically transmitted to a secure server. The treating physician can view and analyze them via password-protected access. Before a WCD is handed to a patient, the WCD is fitted to the patient for accurate ECG signal detection and the patient receives detailed training to ensure correct handling of the WCD.”
 * Source: https://avive.life/blog/wearable-defibrillator/ Patrick98115 (talk) 18:54, 26 June 2024 (UTC)